Dr. Perlmutter's
Whey BrainSustain Tier 3

Whey BrainSustain Tier 3™ is made with whey protein and sweetened with all natural stevia!

30 scoops, 375 grams

Directions: 1 or 2 scoops (12.5-25 grams) daily

Other Ingredients: High lactoferrin whey, pure cane molasses, natural flavors (vanilla bean and oil of orange), potassium bicarbonate, citric acid, not-fat milk solids, stevia extract. Contains ingredients derived from soy and milk.

WARNING: Keep out of reach of children. Consult your healthcare practitioner before taking this product.
TAMPER EVIDENT: Use only if bottle is sealed. Store tightly sealed in a cool dry place.

More information on the potent ingredients in Dr. Perlmutter's BrainSustain

• Coenzyme Q-10 measurably increases the efficiency of cellular energy production, as demonstrated in studies performed at the Massachusetts General Hospital.¹ In addition, it serves as a potent brain antioxidant. These effects explain why major institutions worldwide are vigorously evaluating coenzyme Q10 as a therapeutic aid in brain disorders.
• Alpha Lipoic Acid provides powerful antioxidant action and regenerates other important brain antioxidants including vitamins E, C, and glutathione. Unlike other antioxidants, alpha lipoic acid is both fat- and water-soluble, greatly enhancing its ability to be absorbed from the gut and penetrate into the brain.²
• N-Acetyl-L-Cysteine (NAC) dramatically increases the body's production of glutathione, one of the brain's most important antioxidants. NAC itself is a potent antioxidant shown to reduce formation of nitric oxide, a free radical implicated for a causative role in Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders.³
• Acetyl-L-Carnitine, like coenzyme Q-10, enhances neuronal energy production by transporting fuel sources into the mitochondria — the energy producing machinery of the neuron. This particularly benefits damaged brain neurons, which are characterized by decreased energy production. In addition, acetyl-L-carnitine acts as an effective antioxidant and been demonstrated to protect laboratory animals from developing parkinsonism when they are exposed to chemicals known to induce the condition.⁴ A report in a recent issue of Neurology found that acetyl-L-carnitine profoundly reduces the rate of progression of Alzheimer's disease in younger patients.⁵
• Vitamin E exhibits profound ability to limit free radical damage in the brain — the likely explanation of why it outperformed a highly touted "Alzheimer's drug" in clinical trials reported in the New England Journal of Medicine.⁶ Diets rich in Vitamin E have been shown to reduce the risk of Parkinson's disease by an incredible 61%,⁷ and to dramatically slow disease progression in already-diagnosed patients when supplemented with vitamin C.⁸
• Gingko biloba, one of the most extensively studied nutritional supplements for neurodegenerative conditions, directly improves brain metabolism, increases brain blood flow, and provides antioxidant action. In a placebo-controlled, double-blind randomized trial published in the Journal of the American Medical Association, Gingko biloba not only stabilized Alzheimer's disease, but in addition, many subjects demonstrated an actual improvement noted in various standardized psychological tests.⁹
• Vitamin D may have even greater ability than vitamin E to quench brain free radicals, as described in several reports. Deficiencies of vitamin D have been found in cases of Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis.¹⁰
• Vitamin B12 (Methylcobalamin) is critical for maintaining myelin, the protective coat surrounding each neuron. As with Vitamin D, Vitamin B12 deficiency is associated with neurodegenerative conditions.
• Phosphatidylserine produces marked memory and learning improvements in demented patients, according to research conducted at Stanford University.¹¹ Like acetyl-L-carnitine and coenzyme Q-10, phosphatidylserine plays an important role in neuronal energy production and chemical communication.

References

1. Schults, C.W., Beal, M.F., Fontaine, K., et al. Absorption, tolerability and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonsian patients, Neurology 50: 793-795, 1998. [ Back ^ ]
2. Marangon, K., Deveraj, S., Tirosh, O., et al., Comparison of the effect of a-lipoic acid and a-tocopherol supplementation on measures of oxidative stress. Free Radical Biology and Medicine 27(9/10): 1114-1121, 1999. [ Back ^ ]
3. Pahan, K., Sheikh, G.S., Nmboodri, A.M.S., et al., N-acetyl cysteine inhibits induction of NO production by endotoxin or cytokine stimulated rat peri-toneal macrophages, C6 glial cells and astrocytes. Free Radical Biology and Medicine 24(1):39-48, 1998. [ Back ^ ]
4. Steffen V. Santiago, M., de la Cruz, C.P., et al., Effect of intraventricular injection of 1-methyl-4-phenylpridinium protection by acetyl-L-carnitine. Human Exp Toxicol 14:865-871, 1995. [ Back ^ ]
5. Thal L.J., Carta A. Clarke, W.R., et al., A 1-year multicenter placebo-con-trolled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 47:705-711, 1996. [ Back ^ ]
6. Sano, M., Ernesto, C., Thomas, R.G., et al., A controlled trial of selegeline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N England J Med 336:1216-22, 1997. [ Back ^ ]
7. Golbe, L.I., Farrell, T.M., David, P.H., Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol 45(12): 1350-3, 1988. [ Back ^ ]
8. Fahn, S., The endogenous toxin theory of the etiology of Parkinson's dis-ease and a pilot trial of high-dose antioxidants in an attempt to slow the progression of the illness. Ann N Y Acad Sci 570:186-96, 1989. [ Back ^ ]
9. Le Bars, P., Katz, M.M., Berman, N., et al,. a Placebo-Controlled, Double-blind Randomized Trial of an Extract of Gingko Biloba for Dementia. JAMA 278(16): 1327-32, 1997. [ Back ^ ]
10. Sardar, S., Chakraborty, A., and Chatterjee, M., Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague-Dawley rats. Int J Vitam Nutr Res, 66(1):39-45, 1996. [ Back ^ ]
11. Crook, T.H., Tinklenberg, J., Yesavage, J., Effects of phosphatidylserine in age-associated memory impairment. Neurology 41:644-49, 1991. [ Back ^ ]